TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The investigational drug retatrutide reduced knee osteoarthritis pain and improved physical function in adults with obesity in the 68-week TRIUMPH-4 trial. Participants also lost substantial weight, while adverse-event withdrawals were more frequent than with placebo; whether the drug directly affects joint disease remains unknown.
The investigational drug retatrutide reduced knee pain and improved physical function in adults with obesity and knee osteoarthritis, according to results from the 68-week TRIUMPH-4 trial presented at the American College of Rheumatology annual meeting and published in the New England Journal of Medicine. Participants receiving the drug also lost substantial weight, but the findings do not establish that retatrutide slows or reverses joint damage.
The trial randomized 445 adults with obesity and knee osteoarthritis to weekly injections of placebo, 9 milligrams of retatrutide, or 12 milligrams. Participants had a mean baseline body mass index of 40.4 and an average weight of about 113 kilograms. All groups also received dietary counseling and advice to complete at least 150 minutes of physical activity per week.
At week 68, the mean WOMAC pain score had fallen by 4.48 points with 9 mg and 4.41 points with 12 mg, compared with a 2.43-point decline with placebo. WOMAC is a measure of osteoarthritis pain and related symptoms. Physical-function scores also improved more in the retatrutide groups: declines of 4.14 and 4.20 points, respectively, compared with 2.06 points with placebo. The report says lower scores represent improvement.
Weight loss increased over the study period and had not clearly reached a plateau by week 68, according to the report. The investigators reported that participants lost more than one-quarter of their body weight on average. About 70% of people in each retatrutide group had a 70% reduction in WOMAC pain scores, compared with 26% in the placebo group. These outcomes occurred alongside the lifestyle program, and the placebo group also had improvements in pain and weight.
Pain Relief Alongside Weight Loss
Knee osteoarthritis can limit mobility and daily activities, and excess body weight can increase stress on the knee. In TRIUMPH-4, adults with obesity and knee osteoarthritis who received retatrutide had greater improvements in pain and physical function than those who received placebo, alongside substantial weight loss. The trial tested outcomes in this specific patient group over 68 weeks.
The trial does not show whether the pain improvement came from reduced mechanical loading, changes in inflammation, another drug effect, or a combination. Nor does it establish a benefit for people with osteoarthritis who do not have obesity. The study assessed symptoms and does not establish whether retatrutide changes the underlying joint disease.
Products Worth Considering
BowFlex Results Series SelectTech Adjustable Dumbbells (Pair)
Withings Sleep Under-Mattress Sleep Tracking Pad
Philips Sonicare 5950 Rechargeable Electric Toothbrush with 2 Brush Heads, Pink
As an affiliate, we earn on qualifying purchases.
How Retatrutide Was Tested
Retatrutide is an investigational medicine that acts on three hormone receptors: GLP-1, GIP and glucagon. The source report describes earlier studies as showing greater weight loss than is typically seen with drugs acting on GLP-1 alone. Retatrutide remains investigational; the trial results do not by themselves establish regulatory approval or routine availability.
TRIUMPH-4 followed the TRIUMPH-1 study, and the new findings were released alongside a recap of that earlier trial. The study authors proposed that weight reduction may lessen the load placed on the knee. They also noted that reductions in body fat might affect inflammatory signals, but described these as possible explanations rather than established mechanisms. The study included people with substantial osteoarthritis: the report says 64% had Kellgren-Lawrence grade 3 disease.
Joint Effects Still Unproven
The trial shows improved reported pain and function, but it does not establish that retatrutide prevents cartilage loss or otherwise changes the course of osteoarthritis. The precise reasons for symptom improvement remain uncertain, as does whether similar effects would occur in people with osteoarthritis who are not obese. The available report also does not establish how long benefits persist after treatment ends.
Tolerability is another open issue. Adverse events led to withdrawal in 13% of the 9-mg group and 18% of the 12-mg group, compared with 4% of participants receiving placebo. Serious adverse events were reported in about 10% of both retatrutide groups and 2% of the placebo group. Gastrointestinal problems were the most common adverse events, according to the report. Some participants reportedly left the study because they considered their weight loss excessive. The supplied report excerpt does not provide full details about other adverse events or the causes of serious events.
Further Trials Must Clarify Benefits
The investigators called for further research into how retatrutide might affect osteoarthritis pain and whether it can modify joint disease, rather than only reduce symptoms. Follow-up evidence will also need to clarify the durability of pain and weight changes, the balance of benefits and harms, and whether patients who lose what they consider excessive weight can be identified and supported.
TRIUMPH-4 reported improvements in pain and function during treatment in adults with obesity and knee osteoarthritis, alongside substantial weight loss and more adverse-event withdrawals than placebo. The supplied source does not specify a next trial date or regulatory decision.
Key Questions
What did the TRIUMPH-4 trial find?
In adults with obesity and knee osteoarthritis, retatrutide was associated with larger improvements in WOMAC pain and physical-function scores than placebo over 68 weeks. Participants receiving retatrutide also lost substantial weight.
Does retatrutide cure knee osteoarthritis?
No. The results report improvements in symptoms, but they do not show that retatrutide reverses osteoarthritis or slows joint damage. The investigators said further research is needed to test whether it has a disease-modifying effect.
How much did pain scores change?
Mean WOMAC pain scores fell by 4.48 points with 9 mg and 4.41 points with 12 mg, compared with a 2.43-point decrease with placebo at week 68.
What safety concerns were reported?
Adverse events led to withdrawal for 13% of participants in the 9-mg group and 18% in the 12-mg group, compared with 4% on placebo. Serious adverse events were reported in about 10% of each retatrutide group and 2% of the placebo group; gastrointestinal events were the most common.
Is retatrutide available as an approved osteoarthritis treatment?
The source describes retatrutide as an investigational drug. The trial results reported here do not establish regulatory approval or routine availability for osteoarthritis.
Source: medpagetoday.com
